Potential roles of peroxisomes in alzheimer's disease and in dementia of the alzheimer's type

Journal of Alzheimer's Disease

Volumn 29, Issue 2, 2012, Pages 241-254

  Lizard, Gérard ^a   Rouaud, Olivier ^b   Demarquoy, Jean ^a   Cherkaoui Malki, Mustapha ^a   Iuliano, Luigi ^c  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; carnitine dependent enzymes; dementia; DHA; peroxisome; plasmalogen

Indexed keywords

BILE ACID; CARNITINE; CARNITINE ACETYLTRANSFERASE; DOCOSAHEXAENOIC ACID; ICOSANOID; LONG CHAIN FATTY ACID; MYELIN; PHYTANIC ACID; PLASMALOGEN; VERY LONG CHAIN FATTY ACID;

AGE; ALZHEIMER DISEASE; BILE ACID SYNTHESIS; CELL NUCLEUS; COGNITIVE DEFECT; DISEASE SEVERITY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ERYTHROCYTE; EUKARYOTIC CELL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HUMAN; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OXIDATION; PEROXISOME; PRIORITY JOURNAL; REVIEW;

EID: 84859397583     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111163     Document Type: Review

References (132)

1. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
2. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
3. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
4. Coleman RE (2005) Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin N Am 15, 837-846. (Pubitemid 43162381)
5. Björkhem I (2006) Crossing the barrier: Oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 260, 493-508. (Pubitemid 44772369)
6. Vaya J, Schipper HM (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem 102, 1727-1737. (Pubitemid 47329280)
7. Leoni V, Caccia C (2011) Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 164, 515-524.
8. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL (2007) Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48, 2485-2498. (Pubitemid 350058760)
9. Kou J, Kovacs GG, Höftberger R, Kulik W, Brodde A, Forss-Petter S, Hönigschnabl S, Gleiss A, Brügger B, Wanders R, Just W, Budka H, Jungwirth S, Fischer P, Berger J (2011) Peroxisomal alterations in Alzheimer's disease. Acta Neu-ropathol 122, 271-283.
10. Bazan NG (2009) Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 50 (Suppl), S400-S405.
11. Hayashi M, Toriyama K, Kondo M, Kato A, Mano S, De Bellis L, Hayashi-Ishimaru Y, Yamaguchi K, Hayashi H, Nishimura M (2000) Functional transformationof plant per-oxisomes. Cell Biochem Biophys 32, 295-304.
12. Schrader M, Fahimi HD (2004) Mammalian peroxisomes and reactive oxygen species. Histochem Cell Biol 122, 383-393. (Pubitemid 39506595)
13. Schrader M, Fahimi HD (2008) The peroxisome: Still a mysterious organelle. Histochem Cell Biol 129, 421-440.
14. Lazarow PB, Fujiki Y (1985) Biogenesis of peroxisomes. Annu Rev Cell Biol 1, 489-530.
15. Girzalsky W, Saffian D, Erdmann R (2010) Peroxisomal protein translocation. Biochim Biophys Acta 1803, 724-731.
16. Lanyon-Hogg T, Warriner SL, Baker A (2010) Getting a camel through the eye of a needle: The import of folded proteins by peroxisomes. Biol Cell 102, 245-263.
17. van der Klei LJ, Veenhuis M (2006) PTS1-independent sorting of peroxisomal matrix proteins by Pex5p. Biochim Biophys Acta 1763, 1794-1800.
18. McNew JA, Goodman JM (1994) An oligomeric protein is imported into peroxisomes in vivo. J Cell Biol 127, 1245-1257. (Pubitemid 24362560)
19. Wanders RJ, Waterham HR (2006) Peroxisomal disorders: The single peroxisomal enzyme deficiencies. Biochim Bio-phys Acta 1763, 1707-1720. (Pubitemid 44880473)
20. Wanders RJ, Waterham HR (2006) Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 75, 295-332. (Pubitemid 44118035)
21. Wanders RJ, Ferdinandusse S, Brites P, Kemp S (2010) Peroxisomes, lipid metabolism and lipotoxicity. Biochim Biophys Acta 1801, 272-280.
22. Kemp S, Wanders RJ (2007) X-linked adrenoleukodys-trophy: Very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol Genet Metab 90, 268-276.
23. Jogl G, Hsiao YS, Tong L (2004) Structure and function of carnitine acyltransferases. Ann N Y Acad Sci 1033, 17-29. (Pubitemid 39656735)
24. Ramsay RR, Zammit VA (2004) Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Asp Med 25, 475-493. (Pubitemid 39195072)
25. Depreter M, Espeel M, Roels F (2003) Human peroxisomal disorders. Microsc Res Tech 61, 203-223. (Pubitemid 36570104)
26. Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW (2006) Peroxisome biogenesis disorders. Biochim Biophys Acta 1763, 1733-1748. (Pubitemid 44880484)
27. Baes M, Aubourg P (2009) Peroxisomes, myelination, and axonal integrity in the CNS. Neuroscientist 15, 367-379.
28. Ferrer I, Aubourg P, Pujol A (2010) General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol 20, 817-830.
29. Wanders RJ (2004) Peroxisomes, lipid metabolism, and per-oxisomal disorders. Mol Genet Metab 83, 16-27. (Pubitemid 39311277)
30. Brites P, Waterham HR, Wanders RJ (2004) Functions and biosynthesis of plasmalogens in health and disease. Biochim Biophys Acta 1636, 219-231. (Pubitemid 38780799)
31. Mandel H, Sharf R, Berant M, Wanders RJ, Vreken P, Aviram M (1998) Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: Insights from investigations with plasmalogen-deficient cells. Biochem Biophys Res Commun 250, 369-373. (Pubitemid 28463884)
32. Munn NJ, Arnio E, Liu D, Zoeller RA, Liscum L (2003) Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 44, 182-192. (Pubitemid 36114784)
33. Titorenko VI, Terlecky SR (2011) Peroxisome metabolism and cellular aging. Traffic 12, 252-259.
34. Farooqu AA, Horrocks LA (2001) Plasmalogens, phospho-lipase A2, and docosahexaenoic acid turnoverinbrain tissue. J Mol Neurosci 16, 263-272. (Pubitemid 32664787)
35. Santos MJ, Quintanilla RA, Toro A, Grandy R, Dinamarca MC, Godoy JA, Inestrosa NC (2005) Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J Biol Chem 280, 41057-41068. (Pubitemid 41780601)
36. Lukiw WJ, Bazan NG (2006) Survival signalling in Alzheimer's disease. Biochem Soc Trans 34 (Pt 6), 1277-1282. (Pubitemid 46769037)
37. Terlecky SR, Koepke JI, Walton PA (2006) Peroxisomes and aging. Biochim Biophys Acta 1763, 1749-1754. (Pubitemid 44880468)
38. Cimini A, Moreno S, D'Amelio M, Cristiano L, D'Angelo B, Falone S, Benedetti E, Carrara P, Fanelli F, Cecconi F, Amicarelli F, Cerg̀ MP (2009) Early biochemical and morphological modifications in the brain of a transgenic mouse model of Alzheimer's disease: A role for peroxi-somes. J Alzheimers Dis 18, 935-952.
39. Stillwell W (2008) Docosahexaenoic acid: A most unusual fatty acid. Chem Phys Lipids 153, 1-2.
40. Guesnet P, Alessandri JM (2011) Docosahexaenoic acid (DHA) and the developing central nervous system (CNS)-Implications for dietary recommendations. Biochimie 93, 7-12.
41. Fam SS, Murphey LJ, Terry ES, Zackert WE, Chen Y, Gao L, Pandalai S, Milne GL, Roberts LJ, Porter NA, Montine TJ, Morrow JD (2002) Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivofrom docosahexaenoic acid. J Biol Chem277, 36076-36084.
42. Musiek ES, Cha JK, Yin H, Zackert WE, Terry ES, Porter NA, Montine TJ, Morrow JD (2004) Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. J Chromatogr B Analyt Technol Biomed Life Sci 799, 95-102. (Pubitemid 37500867)
43. Pratico D, Barry OP, Lawson JA, Adiyaman M, Hwang SW, Khanapure SP, Iuliano L, Rokach J, Fitz Gerald GA (1998) IPF2alpha-I: An index of lipid peroxidation in humans. Proc Natl Acad Sci USA 95, 3449-3454.
44. Song WL, Lawson JA, Reilly D, Rokach J, Chang CT, Gias-son B, Fitz Gerald GA (2008) Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem 283, 6-16.
45. Bazan NG (2009) Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids 81, 205-211.
46. Niemoller TD, Bazan NG (2010) Docosahexaenoic acid neurolipidomics. Prostaglandins Other Lipid Mediat 91, 85-89.
47. Lukiw WJ, Bazan NG (2010) Inflammatory, apoptotic, and survival gene signaling in Alzheimer's disease. Mol Neuro-biol 42, 10-16.
48. McGahon BM, Martin DS, Horrobin DF, Lynch MA (1999) Age-related changes in synaptic function: Analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 94, 305-314. (Pubitemid 29457620)
49. Vreugdenhil M, Bruehl C, Voskuyl RA, Kang JX, Leaf A, Wadman WJ (1996) Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci USA 93, 12559-12563. (Pubitemid 26367183)
50. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet AM, Besnard JC, Durand G (1998) Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 128, 2512-2519. (Pubitemid 29013003)
51. Kubo K, Saito M, Tadokoro T, Maekawa A (1998) Dietary docosahexaenoic acid dose not promote lipid peroxidation in rat tissue to the extent expected from peroxidizability index of the lipids. Biosci Biotechnol Biochem 62, 1698-1706. (Pubitemid 128475117)
52. Hossain MS, Hashimoto M, Masumura S (1998) Influence of docosahexaenoic acid on cerebral lipid peroxide level in aged rats with and without hypercholesterolemia. Neurosci Lett 244, 157-160. (Pubitemid 28226315)
53. Bonekamp NA, Volkl A, Fahimi HD, Schrader M (2009) Reactive oxygen species and peroxisomes: Struggling for balance. Biofactors 35, 346-355.
54. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lütjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33, 482-498.
55. Su HM (2010) Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J Nutr Biochem 21, 364-373.
56. Hashimoto M, Katakura M, Hossain S, Rahman A, Shimada T, Shido O (2011) Docosahexaenoic acid withstands the Afj (25-35)-induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem 22, 22-29.
57. Amtul Z, Uhrig M, Rozmahel RF, Beyreuther K (2011) Structural insight into the differential effects of omega-3 and omega-6 fatty acids on the production of Abeta peptides and amyloid plaques. J Biol Chem 286, 6100-6107.
58. Cole GM, Frautschy SA (2010) DHA may prevent age-related dementia. J Nutr 140, 869-874.
59. Jicha GA, Markesbery WR (2010) Omega-3 fatty acids: Potential role in the management of early Alzheimer's disease. Clin Interv Aging 5, 45-61.
60. Barber RC (2010) Biomarkers for early detection of Alzheimer disease. J Am Osteopath Assoc 110 (9 Suppl 8), S10-S15.
61. Gong CX, Grundke-Iqbal I, Iqbal K (2010) Targeting tau protein in Alzheimer's disease. Drugs Aging 27, 351-365.
62. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089.
63. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, LaFerla FM (2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27, 4385-4395. (Pubitemid 46640724)
64. Masood A, Stark K, Salem N Jr (2005) A simplified and efficient method for the analysis of fatty acid methyl esters suitable for large clinical studies. J Lipid Res 46, 2299-2305. (Pubitemid 41377483)
65. Iuliano L, Monticolo R, Straface G, Zullo S, Galli F, Boaz M, Quattrucci S (2009) Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am J Clin Nutr 90, 477-484.
66. Lawson JA, Kim S, Powell WS, Fitz Gerald GA, Rokach J (2006) Oxidized derivatives of omega-3 fatty acids: Identification of IPF3 alpha-VI in human urine. J Lipid Res 47, 2515-2524. (Pubitemid 44936113)
67. Mukherjee P, Marcheselli V, Serhan C, Bazan N (2004) Neuroprotectin D1:A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 101, 8491-8496. (Pubitemid 38736602)
68. Mukherjee PK, Marcheselli VL, Barreiro S, Hu J, Bok D, Bazan NG (2007) Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling. Proc Natl Acad Sci USA 104, 13152-13157. (Pubitemid 351737608)
69. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 304, 1903-1911.
70. Cederholm T, Palmblad J (2010) Are omega-3 fatty acids options for preventionand treatmentofcognitive decline and dementia? Curr Opin Clin Nutr Metab Care 13, 150-155.
71. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115, 2774-2783. (Pubitemid 41434404)
72. Wang W, Shinto L, Connor WE, Quinn JF (2008) Nutritional biomarkers in Alzheimer's disease: The association between carotenoids, n-3 fatty acids, and dementia severity. J Alzheimers Dis 13, 31-38. (Pubitemid 351365625)
73. Lukiw WJ, Bazan NG (2008) Docosahexaenoic acid and the aging brain. J Nutr 138, 2510-2514.
74. Yurko-Mauro K (2010) Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr Alzheimer Res 7, 190-196.
75. Panganamala RV, Horrocks LA, Geer JC, Cornwell DG (1971) Positions of double bonds in the monounsaturated alk-1-enyl groups from the plasmalogens of human heart and brain. Chem Phys Lipids 6, 97-102.
76. Nagan N, Zoeller RA (2001) Plasmalogens: Biosynthesis and functions. Prog Lipid Res 40, 199-229. (Pubitemid 32220187)
77. Farooqui AA, Horrocks LA (1985) Metabolicand functional aspects of neural membrane phospholipids. In: Horrocks LA, Kanfer JN, Porcellati G, (eds.), Phospholipids in the nervous system: Physiological Role, vol. 2. Raven Press, New York, pp. 341-348.
78. Rintala J, Seemann R, Chandrasekaran K, Rosenberger TA, Chang L, Contreras MA, Contreras MA, Rapoport SI, Chang MC (1999) 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10, 3887-3890. (Pubitemid 30004851)
79. Van der Vusse GJ, Reneman RS, van Bilsen M (1997) Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: Possible causes and consequences. Prostaglandins Leukot Essent Fatty Acids 57, 85-93. (Pubitemid 27300223)
80. Ghosh MK, Hajra AK (1986) Subcellular distribution and properties of acyl/alkyl dihydroxyacetone phosphate reduc-tase in rodent livers. Arch Biochem Biophys 245, 523-530. (Pubitemid 16055144)
81. Kovacs WJ, Tape KN, Shackelford JE, Wikander TM, Richards MJ, Fliesler SJ, Krisans SK, Faust PL (2009) Per-oxisome deficiency causes a complex phenotype because of hepatic SREBP/Insig dysregulation associated with endo-plasmic reticulum stress. J Biol Chem 284, 7232-7245.
82. Munn NJ, Arnio E, Liu D, Zoeller RA, Liscum L (2003) Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 44, 182-192. (Pubitemid 36114784)
83. Hale CC, Ebeling EG, Hsu FF, Ford DA (1998) The selective activation of the cardiac sarcolemmal sodium-calcium exchanger by plasmalogenic phosphatidic acid produced by phospholipase D. FEBS Lett 422, 247-251. (Pubitemid 28064553)
84. Teigler A, Komljenovic D, Draguhn A, Gorgas K, Just WW (2009) Defects in myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient mouse cerebellum. Hum Mol Genet 18, 1897-1908.
85. Maeba R, Ueta N (2003) Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method. Biochem Biophys Res Commun 302, 265-270. (Pubitemid 36397915)
86. Ingrand SS, Wahl A, Favreliere S, Barbot F, Tallineau C (2000) Quantification of long-chain aldehydes by gas chro-matography coupled to mass spectrometry as a tool for simultaneous measurement of plasmalogens and their alde-hydic breakdown products. Anal Biochem 280, 65-72. (Pubitemid 30210813)
87. Felde R, Spiteller G (1995) Plasmalogen oxidationin human serum lipoproteins. Chem Phys Lipids 76, 259-267.
88. Weisser M, Spiteller G (1996) Increase of aldehydic compounds derived from plasmalogens in the brain of aged cattle. Chem Phys Lipids 82, 173-178. (Pubitemid 26306628)
89. Jira W, Spiteller G (1996) Plasmalogens and their oxidative degradation products in low and high density lipoprotein. Chem Phys Lipids 79, 95-100. (Pubitemid 26143730)
90. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL (1995) Disease and anatomic specificityofethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res 698, 223-226.
91. Farooqui AA, Rapoport SI, Horrocks LA (1997) Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalogens. Neurochem Res 22, 523-527. (Pubitemid 27184719)
92. Han X, Holtzman DM, McKeel DW Jr (2001) Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77, 1168-1180. (Pubitemid 32467071)
93. Igarashi M, Ma K, Gao F, Kim HW, Rapoport SI, Rao JS (2011) Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis 24, 507-517.
94. Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J, Goodenowe DB (2010) Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35, 59-62.
95. Grimm MO, Kuchenbecker J, Rothhaar TL, Grösgen S, Hundsdörfer B, Burg VK, Friess P, Müller U, Grimm HS, Riemenschneider M, Hartmann T (2011) Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate- synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. J Neurochem 116, 916-925.
96. Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sin-delar PJ (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58, 740-747. (Pubitemid 29328503)
97. Nalecz KA, Miecz D, Berezowski V, Cecchelli R (2004) Carnitine: Transport and physiological functions in the brain. Mol Aspects Med 25, 551-567. (Pubitemid 39195076)
98. Burlina AP, Sershen H, Debler EA, Lajtha A (1989) Uptake of acetyl-L-carnitine in the brain. Neurochem Res 14, 489-493. (Pubitemid 19176629)
99. Parnetti L (1995) Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet 29, 110-129.
100. Ando S, Kobayashi S, Waki H, Kon K, Fukui F, Tade-numa T, Iwamoto M, Takeda Y, Izumiyama N, Watanabe K, Nakamura H (2002) Animal model of dementia induced by entorhinal synaptic damage and partial restorationofcog-nitive deficits by BDNF and carnitine. J Neurosci Res 70, 519-527. (Pubitemid 35222389)
101. Kobayashi S, Iwamoto M, Kon K, Waki H, Ando S, Tanaka Y (2010) Acetyl-L-carnitine improves aged brain function. Geriatr Gerontol Int 10 (Suppl 1), S99-S106.
102. Pettegrew JW, Levine J, McClure RJ (2000) Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 5, 616-632.
103. Lombardo P, Scuri R, Cataldo E, Calvani M, Nicolai R, Mosconi L, Brunelli M (2004) Acetyl-L-carnitine induces a sustained potentiation of the after hyperpolarization. Neuroscience 128, 293-303. (Pubitemid 39200477)
104. Paradies G, Petrosillo G, Gadaleta MN, Ruggiero FM (1999) The effect of aging and acetyl-L-carnitine on the pyruvate transport and oxidation in rat heart mitochondria. FEBS Lett 454, 207-209. (Pubitemid 29304601)
105. Van der Leij FR, Huijkman NC, Boomsma C, Kuipers JR, Bartelds B (2000) Genomics of the human carnitine acyl-transferase genes. Mol Genet Metab 71, 139-153.
106. Piovesan P, Quatrini G, Pacifici L, Taglialatela G, Angelucci L (1995) Acetyl-L-carnitine restores choline acetyltrans-ferase activity in the hippocampus of rats with partial unilateral fimbria-fornix transection. Int J Dev Neurosci 13, 13-19.
107. Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, Lamanna JC, Aliev G (2009) The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci 283, 199-206.
108. Hudson S, Tabet N (2003) Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev, CD003158.
109. McDaniel MA, Maier SF, Einstein GO (2003) "Brain-specific" nutrients: A memory cure? Nutrition 19, 957-975.
110. Montgomery SA, Thal LJ, Amrein R (2003) Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.Int Clin Psychopharmacol 18, 61-71. (Pubitemid 36343974)
111. Bianchetti A, Rozzini R, Trabucchi M (2003) Effects of acetyl-L-carnitine inAlzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin 19, 350-353. (Pubitemid 36827846)
112. Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: A 1-year, open-label pilot study with an 16-month caregiver extension. Am J Alzheimers Dis Other Demen 23, 571-585.
113. Brooks JO 3rd, Yesavage JA, Carta A, Bravi D (1998) Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: A reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 10, 193-203. (Pubitemid 28375550)
114. Kalaria RN, Harik SI (1992) Carnitine acetyltransferase activity in the human brain and its microvessels is decreased in Alzheimer's disease. Ann Neurol 32, 583-586.
115. Makar TK, Cooper AJ, Tofel-Grehl B, Thaler HT, Blass JP (1995) Carnitine, carnitine acetyltransferase, and glutathione in Alzheimer brain. Neurochem Res 20, 705-711.
116. Maurer I, Zierz S, Möller HJ (1998) Carnitine acyltrans-ferases are not changed in Alzheimer disease. Alzheimer Dis Assoc Disord 12, 71-76. (Pubitemid 29108212)
117. Cole GM, Ma QL, Frautschy SA (2009) Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 81, 213-221.
118. McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J Alzheimers Dis 9, 271-276. (Pubitemid 44253320)
119. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. Neuro Rx 1, 226-234. (Pubitemid 46591884)
120. Kuratko CN, Salem N Jr (2009) Biomarkers of DHA status. Prostaglandins Leukot Essent Fatty Acids 81, 111-118.
121. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ 2nd, Kaye JA, Morrow JD (2002) Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52, 175-179. (Pubitemid 34810597)
122. Mazza M, Pomponi M, Janiri L, Bria P, Mazza S (2007) Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Prog Neuropsychophar-macol Biol Psychiatry 31, 12-26. (Pubitemid 44959258)
123. Leonardi F, Attorri L, Benedetto RD, Biase AD, Sanchez M, Tregno FP, Nardini M, Salvati S (2007) Docosahexaenoic acid supplementation induces dose and time dependent oxidative changes in C6 glioma cells. Free Radic Res 41, 748-756. (Pubitemid 46995256)
124. Schumann U, Subramani S (2008) Special delivery from mitochondria to peroxisomes. Trends Cell Biol 18, 253-256.
125. Kassmann CM, Lappe-Siefke C, Baes M, Brügger B, Mildner A, Werner HB, Natt O, Michaelis T, Prinz M, Frahm J, Nave KA (2007) Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 39, 969-976. (Pubitemid 47185174)
126. Bottelbergs A, Verheijden S, Hulshagen L, Gutmann DH, Goebbels S, Nave KA, Kassmann C, Baes M (2010) Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes. Glia 58, 1532-1543.
127. Farooqui AA, Horrocks LA (2001) Plasmalogens: Workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7, 232-245. (Pubitemid 32489117)
128. Novikoff AB, Goldfischer S (1969) Visualization of peroxisomes (microbodies) and mitochondria with diaminobenzi-dine. J Histochem Cytochem 17, 675-680.
129. Baarine M, Ragot K, Genin EC, El Hajj H, Trompier D, Andreoletti P, Ghandour MS, Menetrier F, Cherkaoui-Malki M, Savary S, Lizard G (2009) Peroxisomal and mitochondrial status of two murine oligodendrocytic cell lines (158N, 158JP): Potential models for the study of peroxisomal disorders associated with dysmyelination processes. JNeurochem 111, 119-131.
130. Angermuller S, Fahimi HD (1981) Selective cytochemical localization of peroxidase, cytochrome oxidase and catalase in rat liver with 3, 3'-diaminobenzidine. Histochemistry 71, 33-44. (Pubitemid 11079378)
131. Fahimi HD, Baumgart E (1999) Current cytochemical techniques for the investigation of peroxisomes, A review. J Histochem Cytochem 47, 1219-1232. (Pubitemid 29455917)
132. Fahimi HD (2009) Peroxisomes: 40 years of histochemical staining, personal reminiscences. Histochem Cell Biol 131, 437-440.